{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:56Z","timestamp":1790312396768,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is a leading cause of tumor-related death in women worldwide. Despite treatment advances, survival from metastatic breast cancer is still not satisfactory. Therefore, timely detection of effective treatment is crucial. Changes in receptor status have been reported between primary tumors and metastases. These were mainly due to the changes in the molecular profiles of breast cancer and the heterogeneity within the tumor. Recent studies have suggested that circulating tumor cells (CTCs) can aid prognostic monitoring and guide individualized treatment by assessing chemotherapy sensitivity. Here, we described two cases of HER2-positive breast cancer patients with lung metastasis using CTC drug sensitivity test for individualized treatment. The results suggest that CTC drug sensitivity test demonstrates good value in guiding individualized treatment. Furthermore, the CTC drug sensitivity test results were found to align well with the histopathological results and the patients\u2019 prior tumor resistance information. These observations preliminarily showcase the potential of CTCs to predict metastatic lesions and to identify effective treatments, especially when histopathology is unavailable. In summary, our case report is the first to evaluate CTC drug sensitivity testing in advanced breast cancer, showing its clinical value and feasibility for personalized therapy, and suggests its broad development prospects in the future. However, further research is needed to validate its reliability.<\/jats:p>","DOI":"10.3389\/fonc.2026.1888730","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:57Z","timestamp":1790310417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yangyang","family":"Qian","sequence":"first","affiliation":[{"name":"General Surgery, Cancer center, Department of Breast Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihen","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Center, Department of Radiology, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaochun","family":"Zhong","sequence":"additional","affiliation":[{"name":"General Surgery, Cancer center, Department of Breast Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xia","sequence":"additional","affiliation":[{"name":"General Surgery, Cancer center, Department of Breast Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Department of Radiology, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Kong","sequence":"additional","affiliation":[{"name":"Center for Rehabilitation Medicine, Department of Orthopedics, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21778","article-title":"Metastatic patterns in adenocarcinoma","volume":"106","author":"Hess","year":"2006","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1456599","article-title":"Breast cancer lung metastasis: molecular biology and therapeutic implications","volume":"19","author":"Jin","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2005.08.001","article-title":"Molecular requirements for epithelial-mesenchymal transition during tumor progression","volume":"17","author":"Huber","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12262-012-0616-3","article-title":"Breast cancer stem cells, pathways and therapeutic perspectives 2011","volume":"75","author":"Nigam","year":"2013","journal-title":"Indian J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00129039-200309000-00003","article-title":"erbB-2 (HER-2) and breast cancer progression","volume":"11","author":"Edgerton","year":"2003","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12032-010-9418-2","article-title":"Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent\/metastatic lesions of patients with breast cancer","volume":"28","author":"Sari","year":"2011","journal-title":"Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2882","article-title":"Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma","volume":"13","author":"Tolles","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000458736","article-title":"Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes","volume":"41","author":"Zhang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2014.133","article-title":"Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse\/metastasis","volume":"95","author":"Kantara","year":"2015","journal-title":"Lab Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.7762","article-title":"Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer","volume":"25","author":"Ignatiadis","year":"2007","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0304-3835(99)00114-7","article-title":"Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell","volume":"142","author":"Nakanishi","year":"1999","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-015-1372-1","article-title":"Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis","volume":"18","author":"Lv","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15726","article-title":"Circulating tumor cells derived from advanced hepatocellular carcinoma rapidly develop resistance to cytotoxic chemotherapy","volume":"42","author":"Hsieh","year":"2022","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210218","article-title":"Chemosensitivity evaluation using circulating tumor cells predicts chemotherapy outcomes in patients with advanced cancer","volume":"68","author":"Chen","year":"2022","journal-title":"Clin Lab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12885-015-1423-6","article-title":"The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients","volume":"15","author":"Wallwiener","year":"2015","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-122884","article-title":"Circulating tumour cells, circulating tumour DNA and circulating microRNA in metastatic breast carcinoma - what is the role of liquid biopsy in breast cancer","volume":"77","author":"Polasik","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jtho.2016.07.027","article-title":"Expanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: a case study","volume":"12","author":"Zhang","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164187","article-title":"Unraveling tumor heterogeneity by using DNA barcoding technologies to develop personalized treatment strategies in advanced-stage PDAC","volume":"13","author":"Dujardin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Alix-Panabieres","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1039\/c9lc00210c","article-title":"Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells","volume":"19","author":"Zhao","year":"2019","journal-title":"Lab Chip"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/2211068213494391","article-title":"Circulating tumor cell enrichment based on physical properties","volume":"18","author":"Harouaka","year":"2013","journal-title":"J Lab Autom"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1806-z","article-title":"The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study","volume":"20","author":"Yang","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1723","article-title":"Patient-derived tumor-like cell clusters for drug testing in cancer therapy","volume":"12","author":"Yin","year":"2020","journal-title":"Sci Transl Med"},{"key":"B31","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2021\n          \n          2021"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:59Z","timestamp":1790310419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1888730"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1888730","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1888730"}}